Kannan K. Puthuval

Rose Park Research Main: 312-600-4057

La Habra Heights, California Email: kannan.puthuval@gmail.com

Clinical Research Experience

• A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir

- LA Study of Baricitinib in Participants With Rheumatoid Arthritis (RA-BRANCH)
- A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO)
- A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-Year-Old Healthy Adults
- CNP-201 in Subjects With Peanut Allergy
- A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults
- A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥ 50 Years of Age (RSVictory)
- A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of XXXX and XXXX in Participants with Mild to Moderate COVID-19 Illness
- A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety
 of Mono and Combination Therapy with Monoclonal Antibodies in Participants with Mild to Moderate
 COVID-19 Illness
- A Phase II/III seamless, randomised, double-blind, placebo-controlled, parallel-group, group-sequential study to evaluate efficacy, safety and tolerability of XXXX for the treatment of symptomatic, non-hospitalized adults with mild to moderate COVID-19
- A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of XXXX in Outpatients with Mild to Moderate COVID-19 Illness
- A Phase 2/3 Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of XXXX in the Prevention of COVID 19
- A Safety, Tolerability, and Efficacy Study of XXXX in Ambulatory Patients with COVID-19

Professional Experience

- Site Manager & Lead Research Coordinator, Smart Cures Clinical Research, 2020 present.
- Director, Rose Park Research, 2020 present.
- Clinical Research Coordinator, Long Beach Clinical Trials, 2020 present.

Kannan K. Puthuval 2

- Clinical Research Coordinator, Next Level Clinical Trials, 2022 present.
- Software Engineer, The Scotts Company, 2017 2020.
- Chief Scientist & Director of Product Development, Oso Technologies, 2015 2017.
- Research Coordinator, University of Illinois SoyFACE Project, 2012 2015.
- Research Technician, University of Illinois SoyFACE Project, 2009 2012.

Patents

• Mane, M., Singer, D., Puthuval, K. (2018) *USD829574S1* Retrieved from http://patft1.uspto.gov/netacgi/nph-Parser?patentnumber=D829574

Publications

- Gray, S.B., Strellner, R.S., Puthuval, K.K., Ng, C., Shulman, R.E., Siebers, M.H., Rogers, A., and Leakey, A.D.B. (2013). Minirhizotron imaging reveals that nodulation of field-grown soybean is enhanced by free-air CO₂ enrichment only when combined with drought stress. *Functional Plant Biology* 40, 137-147.
- Gray, S.B., Strellner, R.S., Puthuval, K.K., and Leakey, A.D.B. (2011). Elevated CO₂ increases stomatal closure under reduced soil moisture in soybean (Glycine max). American Society of Plant Biologists Annual Meeting. Minneapolis, MN.
- Gray, S.B., Strellner, R.S., Puthuval, K., and Leakey, A.D.B. (2010). Free-air CO₂ enrichment does not lessen the impact of drought on soybean photosynthesis under field conditions. *The Ecological Society of America 95th Annual Meeting.* Pittsburgh, PA.

Education & Certifications

- B.S. Integrative Biology, University of Illinois, 2007
- AHA BLS Provider #205509793972, 2020
- EMT-Basic, 2021
- Good Clinical Practice, 2020 (current)
- IATA Dangerous Goods Packaging and Shipment, 2020 (current)

Service & Other Experience

- Engineer, Engineers Without Borders UIUC Nigeria Water Project, 2011 2012
- Foreign English Teacher, Jishou University, Hunan Province, China, 2007 2008
- Co-Director, The Bike Project of Urbana-Champaign, 2005 2007

Last updated: November 15, 2022